BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 8281952)

  • 1. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of left ventricular hypertrophy.
    Cruickshank JM
    Blood Press Suppl; 1992; 1():32-3; discussion 33-4. PubMed ID: 1343270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect.
    Grandi AM; Laurita E; Solbiati F; Marchesi C; Maresca AM; Nicolini E; Guasti L; Venco A
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):207-11. PubMed ID: 17110802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
    Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophy to failure.
    Tanser PH
    J Hum Hypertens; 1994 Sep; 8 Suppl 1():S17-20. PubMed ID: 7807508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Course of the left ventricular mass in a population of 893 hypertensive patients. Effects of treatment with perindopril].
    Revel F; Gallois H; Le Coz Y; Richard R; Ollivier JP
    Ann Cardiol Angeiol (Paris); 1994 Dec; 43(10):594-9. PubMed ID: 7864552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.